Recent Updates
Recently added Catalysts
PFE Positive Sentiment

Riassunto: Enodia Therapeutics annuncia una collaborazione di ricerca e un accordo di licenza con Pfizer per sviluppare piccole molecole mirate al complesso Sec61

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Enodia Therapeutics has announced a research collaboration and licensing agreement with Pfizer to develop inhibitors targeting the Sec61 complex. This partnership aims to accelerate the discovery and development of new small molecule drugs using Enodia's proprietary platform. The collaboration signifies a strategic move towards innovative therapeutic solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with Pfizer enhances research capabilities.
  • Focus on developing targeted small molecule therapies.
  • Utilization of Enodia's proprietary platform for drug discovery.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+6%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
ibuzatrelvir
Phase 3 · COVID-19 Infection

Full Press Release Details

PARIGI--(BUSINESS WIRE)--Enodia Therapeutics, azienda biotecnologica che sviluppa nuove terapie a piccole molecole per la degradazione mirata delle proteine al punto di sintesi, oggi ha annunciato la firma di un accordo di collaborazione e di licenza con Pfizer Inc. per scoprire e sviluppare inibitori del complesso Sec61. La collaborazione mira ad accelerare la scoperta e il progresso di nuovi farmaci a piccole molecole utilizzando la piattaforma proprietaria di Enodia. La piattaforma proprieta

Frequently Asked Questions

What is the focus of the Enodia and Pfizer collaboration?

The collaboration aims to develop inhibitors targeting the Sec61 complex.

What type of therapies is Enodia Therapeutics developing?

Enodia is developing small molecule therapies for targeted protein degradation.

What platform will be used in the collaboration?

The collaboration will utilize Enodia's proprietary drug discovery platform.

What is the goal of the partnership with Pfizer?

The goal is to accelerate the discovery and development of new small molecule drugs.

ShareAdd on Google
Tags: PFE Enodia Therapeutics Pfizer Sec61 complex small molecules drug discovery
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$11699M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ibuzatrelvirPhase 3
COVID-19 Infection →

Catalyst track record

+6%
best trade around PFE's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →